Lance Liotta

Biography

  Dr. Liotta is one of the inventors of the Nanotrap® technology. As the Medical Director for Ceres, Dr. Liotta provides technical guidance and oversees key components of Ceres Nanosciences' clinical laboratory operations and is a Principal Investigator for many of Ceres' clinical studies, and leads many of the development efforts for Ceres' novel Lyme antigen test and other tick-borne testing applications.    Dr. Liotta is currently the Co-Director for the Center for Applied Proteomics and Molecular Medicine at GMU. He also is Professor at the Department of Molecular and Microbiology at GMU. Dr. Liotta has over 30 years experience in medical research and development. Previous positions held include: Deputy Director for Research, NIH, Co-Director NCI/FDA Clinical Proteomics Program, Director Anatomic Pathology Residency Program, Laboratory of Pathology (National Cancer Institute, NIH), Chief, Laboratory of Pathology (National Cancer Institute, NIH), Chief, Tumor Invasion and Metastases Section (Laboratory of Pathology, NCI, NIH). While at the NIH, Dr. Liotta was the Director of the CAP/CLIA Laboratory for Anatomic Pathology, and held the CAP license for nearly 15 years. Dr. Liotta currently has over 608 peer reviewed publications and in excess of 90 patents issued and/or allowed.    Dr. Liotta and Dr. Petricoin began their proteomics collaboration in 1997, which led to the formation of the first Interagency Agreement between NCI and FDA to develop and test technologies for proteomic analysis—the study of protein activity in cells—of cancer and other diseases. Their renowned collaboration has produced more than 100 publications and numerous proteomic processes to develop new methods for diagnosis and treatment of diseases   Dr. Liotta holds a B.S., Ph.D., and M.D. from Case Western Reserve University.

Research Interest

proteomics, Pathology